5 articles
Kneat's board unanimously endorsed a sale, urging shareholders to vote for it, citing sharp deceleration in annual recurring revenue growth from 51% to 20% year-over-year. The board flagged continued unprofitability and dependence on uncertain large-customer expansions as factors weakening the company's standalone value and leverage if the deal collapses.
Gilead Sciences and Lakefront Biotherapeutics completed the acquisition of Ouro Medicines on June 4, 2026, with deal terms giving Lakefront at least $500 million in independently deployable capital. The Ouro portfolio forms the foundation of Lakefront's R&D pipeline as biotech M&A accelerates ahead of JAKAFI's 2028 patent cliff. Clinical data from EHA 2026 is reinforcing demand for next-generation modalities across T-cell engagers, in vivo CAR-T, and JAK2 inhibitors.
PROG Holdings closed its acquisition of Purchasing Power immediately following its Q4 2025 earnings release and 2026 forward guidance. The timing suggests management deployed capital with clear visibility into future performance, a pattern emerging among companies issuing strong guidance early in fiscal periods.
Eaton's acquisition of Boyd Thermal, announced in 2025, faces potential regulatory hurdles as merger control authorities assess the thermal management deal. The transaction could encounter delays or conditions as antitrust reviewers examine the combination's impact on liquid cooling and data center infrastructure markets. The outcome carries implications for deal completion timelines and strategic M&A planning in industrial technology sectors.
Athens Strategies Ltd.'s merger agreement to acquire CyberArk may encounter regulatory delays from antitrust authorities in Israel, the US, and EU. The cybersecurity sector's strategic importance has triggered medium-likelihood scrutiny that could block or reshape the transaction. Regulatory risk now ranks as the primary concern for investors evaluating the deal.